Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

Adrienne Y.L. Chan; Andrew S.C. Yuen; Daniel H.T. Tsai; Wallis C.Y. Lau; Yogini H. Jani; Yingfen Hsia; David P.J. Osborn; Joseph F. Hayes; Frank M.C. Besag; Edward C.C. Lai; Li Wei; Katja Taxis; Ian C. K. Wong; Kenneth K.C. Man

doi:10.1038/s41467-023-40637-8

Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

Adrienne Y.L. Chan, Andrew S.C. Yuen, Daniel H.T. Tsai, Wallis C.Y. Lau, Yogini H. Jani, Yingfen Hsia, David P.J. Osborn, Joseph F. Hayes, Frank M.C. Besag, Edward C.C. Lai, Li Wei, Katja Taxis, Ian C. K. Wong, Kenneth K.C. Man

Research output: Contribution to journal › Article › peer-review

Abstract

Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.

Original language	English
Article number	5005
Number of pages	11
Journal	Nature Communications
Volume	14
Issue number	1
Early online date	17 Aug 2023
DOIs	https://doi.org/10.1038/s41467-023-40637-8
Publication status	Published - Dec 2023

Bibliographical note

Copyright © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

Keywords

Behavior, Addictive
Commerce
Income
Longitudinal Studies
Policy

Access to Document

10.1038/s41467-023-40637-8

AYL Chan et al_Gabapentinoid consumption in 65 countries and regions from 2008 to 2018
Copyright © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
Final published version, 1.75 MBLicence: CC BY 4.0

Cite this

Chan, A. Y. L., Yuen, A. S. C., Tsai, D. H. T., Lau, W. C. Y., Jani, Y. H., Hsia, Y., Osborn, D. P. J., Hayes, J. F., Besag, F. M. C., Lai, E. C. C., Wei, L., Taxis, K., Wong, I. C. K., & Man, K. K. C. (2023). Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study. Nature Communications, 14(1), Article 5005. https://doi.org/10.1038/s41467-023-40637-8

@article{5759015a0c2e451bbb5536a36be3c7b4,

title = "Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study",

abstract = "Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.",

keywords = "Behavior, Addictive, Commerce, Income, Longitudinal Studies, Policy",

author = "Chan, {Adrienne Y.L.} and Yuen, {Andrew S.C.} and Tsai, {Daniel H.T.} and Lau, {Wallis C.Y.} and Jani, {Yogini H.} and Yingfen Hsia and Osborn, {David P.J.} and Hayes, {Joseph F.} and Besag, {Frank M.C.} and Lai, {Edward C.C.} and Li Wei and Katja Taxis and Wong, {Ian C. K.} and Man, {Kenneth K.C.}",

note = "Copyright {\textcopyright} The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article{\textquoteright}s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article{\textquoteright}s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/ ",

year = "2023",

month = dec,

doi = "10.1038/s41467-023-40637-8",

language = "English",

volume = "14",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

AU - Chan, Adrienne Y.L.

AU - Yuen, Andrew S.C.

AU - Tsai, Daniel H.T.

AU - Lau, Wallis C.Y.

AU - Jani, Yogini H.

AU - Hsia, Yingfen

AU - Osborn, David P.J.

AU - Hayes, Joseph F.

AU - Besag, Frank M.C.

AU - Lai, Edward C.C.

AU - Wei, Li

AU - Taxis, Katja

AU - Wong, Ian C. K.

AU - Man, Kenneth K.C.

N1 - Copyright © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

PY - 2023/12

Y1 - 2023/12

N2 - Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.

AB - Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.

KW - Behavior, Addictive

KW - Commerce

KW - Income

KW - Longitudinal Studies

KW - Policy

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85168274568&partnerID=MN8TOARS

UR - https://www.nature.com/articles/s41467-023-40637-8

U2 - 10.1038/s41467-023-40637-8

DO - 10.1038/s41467-023-40637-8

M3 - Article

C2 - 37591833

SN - 2041-1723

VL - 14

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 5005

ER -

Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this